VRTX Stock: Revenue In Line — Q1 2026 Earnings Analysis

## Chapters 0:00 Snapshot Overview Vertex Pharmaceuticals just reported Q1 2026 earnings — revenue in line. We break down what went wrong and whether VRTX can recover. 🔔 Subscribe for weekly deep dives on every Russell 1000 earnings report: https://www.youtube.com/@ChargedAlpha?sub_confirmation=1 📊 Key Financial Highlights: • Revenue: $3.0B vs $3.0B expected (-0.2% miss) • EPS: $4.06 vs $4.23 expected (-4.0% miss) 📈 Free stock screening tools — no signup, no paywall: https://chargedalpha.com 🎧 Also available as a podcast: https://chargedalpha.podbean.com #stocks #VRTX #earnings #stocks #investing #stockmarket #earningsseason #wallstreet #VertexPharmaceuticals --- Financial data and charts: Financial Modeling Prep (https://financialmodelingprep.com) ⚖️ Disclaimer: This video is for informational and educational purposes only. Nothing discussed constitutes a buy, sell, or hold recommendation. All investments carry risk. Past performance does not guarantee future results. Always do your own research and consult a qualified financial advisor. Hosts may hold positions in securities discussed. This episode was researched, written, and produced using AI-assisted tools. Data sourced from public filings and may contain inaccuracies. Watch on YouTube: https://www.youtube.com/watch?v=IaNGmHGsNeo